All In MedTech

Device Trial Radar · NCT07298473

Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Apr 8, 2026

Primary completion

Mar 29, 2028

Study completion Mar 29, 2028

Sponsor

Lead sponsor
Medtronic Cardiac Ablation SolutionsPublic (MDT)
Sponsor type
Industry
First posted
Dec 23, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single prior ablation procedure will be enrolled in this study. Each subject will undergo a study index redo ablation procedure using the Sphere-9 Catheter and Affera Ablation System and will be followed for 12 months. The expected total study duration (from time of first enrollment to the exit of last enrolled subject) is approximately 2 years.

Conditions

  • Atrial Fibrillation (AF)
  • Persistent Atrial Fibrillation
  • Paroxysmal Atrial Fibrillation (PAF)

Interventions

  • Sphere-9 Catheter AblationDevice

    Redo atrial fibrillation ablation performed using the Sphere-9 Catheter in conjunction with the Affera Ablation System and Affera Mapping System. The intervention delivers radiofrequency and pulsed field energy according to the study protocol for treatment of recurrent paroxysmal or persistent AF. All participants receive this device-based ablation procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness: Number of Participants With Treatment Success.Time frame: 12-months post-redo ablation procedure
  2. Safety: Number of Participants With at Least One Primary Safety EventTime frame: 6-months post-redo ablation procedure

Locations

30 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB) Hospital

    Birmingham, Alabama · Recruiting

  • Scripps Green Hospital

    La Jolla, California · Not yet recruiting

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

27 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.